Haemonetics Corporation (HAE) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Humanetics Corporation first quarter, 2026 earnings call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising you that your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Olga Gayet, Vice President, Investor Relations and Treasury. Olga, you have the floor. Good morning and thank you for joining us for Humanetics first quarter fiscal year 2026 conference call and webcast. I'm joined today by Chris Simon, our CEO, and James Zarecka, our CFO. This morning, we posted our first quarter fiscal year 2026 results and full year fiscal 2026 guidance to our Investor Relations website. The same information was made available via the press release issued this morning. As we provide our business and financial update this morning, I would like to remind everyone that we will use both reported and organic revenue growth numbers that exclude the impact of effects, the divestiture of the whole blood business, and the exit of liquid solution products. Organic revenue growth X-CSL also excludes the impact of the previously discussed transition of CSL's US disposables business. We'll also refer to other non-GAAP financial measures to help investors understand Humanetics ongoing business performance. Please note that these measures exclude certain charges and income items. A full list of excluded items, reconciliations to our GAAP results and compari...